Roche opens new centre for pharmaceutical research
With a total investment of 1.2 billion Swiss francs, Roche has opened a state-of-the-art research and development centre in Basel. The new centre brings together researchers from various disciplines and strengthens the global innovative power of the pharmaceutical company. Further investments totalling billions in the Basel site are already being planned.
A significant milestone has been reached at Roche’s headquarters in Basel. The inauguration of the new Pharma Research and Early Development Centre (pRED). The centre, which offers 1,800 state-of-the-art workstations for laboratory and office work, brings together experts from various fields of research. The aim is to increase the efficiency of research and development through close collaboration. Federal Councillor Guy Parmelin also attended the opening ceremony, which emphasises the national importance of this project.
With the new pRED Centre, Roche is pursuing a clear vision of pooling expertise from areas such as chemistry, biology and data science in order to drive forward pioneering innovations. Thomas Schinecker, CEO of the Roche Group, emphasised the central role of the centre in the company’s global innovation network. “This centre will not only improve the efficiency of our research, but also help us to achieve the greatest possible benefit for patients worldwide.”
Investing billions in the future
The investment in the pRED Centre is part of Roche’s long-term commitment to the Basel site. Since 2009, the company has invested 4.6 billion Swiss francs in the expansion of the site. With the new four buildings – including two high-rise laboratory buildings, an office complex and a congress centre – Roche is sending another strong signal for the future.
And this is just the beginning: a further 1.2 billion Swiss francs are being invested in modernising and expanding the site, which will strengthen Basel’s role as a global centre for pharmaceutical research and development in the long term.
With the opening of the new pRED Centre, Roche is not only investing in its own innovative strength, but also in strengthening Basel as a business location. This billion-euro investment is a clear signal that the pharmaceutical company intends to further expand its leading role in global research and development – a significant step both for the industry and for the region.